Nicholas Jacobus

CDC vaccine advisers delay Hepatitis B schedule changes while recommending separate vaccines for measles, mumps, rubella, and chickenpox amid safety concerns.

Biogen expands its drug delivery solutions by acquiring Alcyone Therapeutics, enhancing patient-centered therapies with the innovative ThecaFlex DRx system.

VectorY Therapeutics partners with Shape Therapeutics to advance innovative therapies for neurodegenerative diseases using SHP-DB1 technology and AAV5 capsids.

Rob DeWig, VP of Healthcare Sales at Inmar, touches on looming DSCSA enforcement and the impact of Inmar's reconciliation tools.

In today’s Pharmaceutical Executive Daily, we explore how AI is disrupting higher education and career pathways, AllRock Bio’s $50 million Series A funding to advance its lead molecule, and FDA warning letters issued to Novo Nordisk, Eli Lilly, and Hims over misleading drug advertising.

Former CDC director Susan Monarez raises alarms about potential changes to childhood vaccine schedules, warning of increased health risks for children.

Novo Nordisk's shares rise as Phase III trial shows its oral Wegovy pill achieves significant weight loss, offering a new option for patients.

Roche strengthens its pipeline by acquiring 89bio and its promising MASH treatment, Pegozafermin, enhancing options for metabolic disease therapies.

Rob DeWig, Vice President of Healthcare Sales, Inmar, touches on the impact of Inmar and Premier's expanded agreement on the broader healthcare and pharmacy ecosystems.

In today’s Pharmaceutical Executive Daily, we cover Lilly’s orforglipron as a prime candidate for FDA fast-track approval, Merck and Daiichi Sankyo’s breakthrough therapy designation for R-DXd in ovarian cancer, and Novo Nordisk’s EU approval of Rybelsus for reducing cardiovascular risk.

FDA warns major pharmaceutical companies to improve transparency in drug advertising, addressing misleading claims and enforcing stricter regulations.

VarmX partners with CSL to advance VMX-C001, a groundbreaking treatment for patients on FXa DOACs, enhancing surgical outcomes and patient care.

Eli Lilly's Orforglipron shows superior results in glycemic control and weight loss compared to oral semaglutide in recent clinical trials.

In today’s Pharmaceutical Executive Daily, we cover AbbVie’s stock jump following a Rinvoq litigation settlement, new insights into the ROI of specialty pharmacy adherence programs, and a closer look at what true innovation in PBM management entails.

AllRock Bio secures $50 million to advance Roc-101, a promising treatment for pulmonary hypertension, aiming to transform patient care.

Novo Nordisk's Rybelsus gains EU approval for cardiovascular benefits, enhancing treatment options for type 2 diabetes and improving patient outcomes.

Eli Lilly's Orforglipron may become the first drug fast-tracked under the FDA's new program, promising quicker access for weight loss treatment.

In today’s Pharmaceutical Executive Daily, we cover Novo Nordisk’s return-to-office mandate from its CEO, the evolving COVID-19 vaccine landscape in 2025, and Capsida’s decision to halt a gene therapy trial following a patient death.

AstraZeneca pauses its £271 million Cambridge investment, reflecting growing concerns over the U.K.'s life sciences sector and government support.

Novartis partners with Monte Rosa Therapeutics in a $5.7 billion deal to develop innovative treatments for immune-mediated diseases using AI technology.

It seems there is no text provided for summarization. Please provide the text you'd like summarized, and I'll be happy to help!

In today’s Pharmaceutical Executive Daily, we cover the president’s call to lower drug costs for patients, the compliance and operational pressures facing pharmaceutical manufacturers, and a White House plan to restrict treatments discovered in China.

AbbVie’s stock surges 4.4% after securing 12 more years of exclusivity for Rinvoq, boosting sales projections and investor confidence.

Novo Nordisk urges employees back to the office while announcing 9,000 job cuts to streamline operations and enhance decision-making.

Helen Sabzevari, PhD, president and CEO of Precigen, explains how Papzimeos transforms clinical practice by establishing the first FDA-approved standard of care for recurrent respiratory papillomatosis (RRP), shifting treatment from repeated surgeries to an immunotherapy that addresses the root HPV infection, with future plans to expand into pediatric populations and redosing strategies.

Pharmaceutical Executive Daily highlights major industry shifts, including job cuts at Lundbeck and Novo Nordisk, and Trump's critique of drug advertising practices.

White House plans potential restrictions on Chinese-developed drugs, sparking lobbying from investors and pharmaceutical giants amid national security concerns.

Intercept Pharmaceuticals withdraws Ocaliva from the U.S. market following FDA concerns over safety and effectiveness for treating primary biliary cholangitis.

Merck withdraws from its London research facility, highlighting growing concerns over the UK's life sciences investment climate and industry competitiveness.

Helen Sabzevari, PhD, president and CEO of Precigen, reflects on how Papzimeos sets an important precedent for rare disease therapies, with its broad FDA label for all adult patients with recurrent respiratory papillomatosis (RRP) highlighting the potential for earlier intervention to prevent irreversible damage and establish new standards of care.